Compare EIG & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | GERN |
|---|---|---|
| Founded | 2000 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.6M | 1.0B |
| IPO Year | 2006 | 1996 |
| Metric | EIG | GERN |
|---|---|---|
| Price | $47.67 | $0.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $54.00 | $3.63 |
| AVG Volume (30 Days) | 143.7K | ★ 14.6M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $858,700,000.00 | $1,065,000.00 |
| Revenue This Year | N/A | $27.99 |
| Revenue Next Year | N/A | $44.91 |
| P/E Ratio | $17.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.44 | $0.84 |
| 52 Week High | $53.51 | $2.01 |
| Indicator | EIG | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 39.98 |
| Support Level | $41.49 | $0.84 |
| Resistance Level | $51.18 | $1.67 |
| Average True Range (ATR) | 1.79 | 0.09 |
| MACD | -0.39 | -0.00 |
| Stochastic Oscillator | 34.41 | 36.08 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.